scholarly journals T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models

Viruses ◽  
2017 ◽  
Vol 9 (4) ◽  
pp. 77 ◽  
Author(s):  
Alan Watson ◽  
William Klimstra
2019 ◽  
Vol 93 (14) ◽  
Author(s):  
Lisa Miorin ◽  
Maudry Laurent-Rolle ◽  
Giuseppe Pisanelli ◽  
Pierre Hendrick Co ◽  
Randy A. Albrecht ◽  
...  

ABSTRACT The recent yellow fever virus (YFV) epidemic in Brazil in 2017 and Zika virus (ZIKV) epidemic in 2015 serve to remind us of the importance of flaviviruses as emerging human pathogens. With the current global flavivirus threat, there is an urgent need for antivirals and vaccines to curb the spread of these viruses. However, the lack of suitable animal models limits the research questions that can be answered. A common trait of all flaviviruses studied thus far is their ability to antagonize interferon (IFN) signaling so as to enhance viral replication and dissemination. Previously, we reported that YFV NS5 requires the presence of type I IFN (IFN-α/β) for its engagement with human signal transducer and activator of transcription 2 (hSTAT2). In this manuscript, we report that like the NS5 proteins of ZIKV and dengue virus (DENV), YFV NS5 protein is able to bind hSTAT2 but not murine STAT2 (mSTAT2). Contrary to what has been demonstrated with ZIKV NS5 and DENV NS5, replacing mSTAT2 with hSTAT2 cannot rescue the YFV NS5-STAT2 interaction, as YFV NS5 is also unable to interact with hSTAT2 in murine cells. We show that the IFN-α/β-dependent ubiquitination of YFV NS5 that is required for STAT2 binding in human cells is absent in murine cells. In addition, we demonstrate that mSTAT2 restricts YFV replication in vivo. These data serve as further impetus for the development of an immunocompetent mouse model that can serve as a disease model for multiple flaviviruses. IMPORTANCE Flaviviruses such as yellow fever virus (YFV), Zika virus (ZIKV), and dengue virus (DENV) are important human pathogens. A common flavivirus trait is the antagonism of interferon (IFN) signaling to enhance viral replication and spread. We report that like ZIKV NS5 and DENV NS5, YFV NS5 binds human STAT2 (hSTAT2) but not mouse STAT2 (mSTAT2), a type I IFN (IFN-α/β) pathway component. Additionally, we show that contrary to what has been demonstrated with ZIKV NS5 and DENV NS5, YFV NS5 is unable to interact with hSTAT2 in murine cells. We demonstrate that mSTAT2 restricts YFV replication in mice and that this correlates with a lack of IFN-α/β-induced YFV NS5 ubiquitination in murine cells. The lack of suitable animal models limits flavivirus pathogenesis, vaccine, and drug research. These data serve as further impetus for the development of an immunocompetent mouse model that can serve as a disease model for multiple flaviviruses.


Immunology ◽  
2009 ◽  
Vol 128 (1pt2) ◽  
pp. e718-e727 ◽  
Author(s):  
Mary Dawn T. Co ◽  
Elizabeth D. Kilpatrick ◽  
Alan L. Rothman

2017 ◽  
Vol 48 (2) ◽  
pp. 258-272 ◽  
Author(s):  
Amandine Bovay ◽  
Vincent Zoete ◽  
Garry Dolton ◽  
Anna M. Bulek ◽  
David K. Cole ◽  
...  

2009 ◽  
Vol 183 (12) ◽  
pp. 7919-7930 ◽  
Author(s):  
Rama S. Akondy ◽  
Nathan D. Monson ◽  
Joseph D. Miller ◽  
Srilatha Edupuganti ◽  
Dirk Teuwen ◽  
...  

2013 ◽  
Vol 190 (5) ◽  
pp. 2150-2158 ◽  
Author(s):  
Kim Blom ◽  
Monika Braun ◽  
Martin A. Ivarsson ◽  
Veronica D. Gonzalez ◽  
Karolin Falconer ◽  
...  

Proceedings ◽  
2020 ◽  
Vol 50 (1) ◽  
pp. 97
Author(s):  
Jinhua Xiang ◽  
James H. McLinden ◽  
Qing Chang ◽  
Thomas M Kaufman ◽  
Judy A. Streit ◽  
...  

Background: A Src kinase-activating phosphatase (PTPRE) is targeted by a genome-derived yellow fever virus (YFV) short noncoding RNA (vsRNA) in vitro. The vsRNA reduces PTPRE translation, which leads to reduced TCR signaling. vsRNA point mutations restore PTPRE expression and T cell function. We examined TCR signaling and PTPRE levels in individuals before and after YFV vaccination (YFVax). Methods: Fourteen individuals receiving YFVax (104.7–5.6) IM for travel prophylaxis provided written informed consent for these studies. Blood was obtained once before vaccination and four times after vaccination (days 3 to 28). Serum and PBMCs were purified and YFV was quantified by RNA and infectivity. PBMCs were assessed for activation following anti-CD3 stimulation by measuring phospho-tyrosine-394-Lck and IL-2 release. PBMC PTPRE levels were determined by immunoblot analyses (normalized to actin). A YFV-neutralizing antibody was determined by PRNT. Results: YFVax was administered alone (six out of 14 subjects) or in combination with other vaccines (eight out of 14). All subjects demonstrated reduced resting PBMC PTPRE levels and post-TCR stimulation had reduced IL-2 release between days 4 and 21 compared to pre- and day 28 samples. Phospho-Lck was reduced in all but two subjects on the same days, and both of these subjects also received an influenza vaccine. Low-level viremia was detected in 10/14 subjects, with infectious titers of 100/mL. Viremia was not detected in four out of 14 subjects. All recipients developed neutralizing antibodies by day 21. Conclusion: YFV vaccination regulates PBMC PTPRE levels 4–21 days after infection, despite the low to absent infectious YFV detected in serum, suggesting that enough YFV vsRNA is produced and released from cells to have a functional (and measurable) effect on T cell function. Studies are underway to determine if this is mediated by exosomes or defective particles containing the vsRNA that targets PTPRE. Furthermore, the association between PTPRE and TCR signaling confirms a role for PTPRE in TCR function.


2017 ◽  
Vol 216 (9) ◽  
pp. 1164-1175 ◽  
Author(s):  
James H McLinden ◽  
Nirjal Bhattarai ◽  
Jack T Stapleton ◽  
Qing Chang ◽  
Thomas M Kaufman ◽  
...  

Virology ◽  
2008 ◽  
Vol 378 (1) ◽  
pp. 105-117 ◽  
Author(s):  
Milton Maciel ◽  
Srinivasan N. Kellathur ◽  
Pryia Chikhlikar ◽  
Rafael Dhalia ◽  
John Sidney ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document